What is the official website of Novogene Europe ?

The official website of Novogene Europe is http://en.novogene.com.

What is Novogene Europe's cybersecurity risk score?

Novogene Europe has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novogene Europe experienced?

According to Rankiteo, Novogene Europe currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novogene Europe been affected by any supply chain cyber incidents ?

According to Rankiteo, Novogene Europe has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novogene Europe have SOC 2 Type 1 certification ?

According to Rankiteo, Novogene Europe is not certified under SOC 2 Type 1.

Does Novogene Europe have SOC 2 Type 2 certification ?

According to Rankiteo, Novogene Europe does not hold a SOC 2 Type 2 certification.

Does Novogene Europe comply with GDPR ?

According to Rankiteo, Novogene Europe is not listed as GDPR compliant.

Does Novogene Europe have PCI DSS certification ?

According to Rankiteo, Novogene Europe does not currently maintain PCI DSS compliance.

Does Novogene Europe comply with HIPAA ?

According to Rankiteo, Novogene Europe is not compliant with HIPAA regulations.

Does Novogene Europe have ISO 27001 certification ?

According to Rankiteo,Novogene Europe is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novogene Europe operate in ?

Novogene Europe operates primarily in the Biotechnology Research industry.

How many employees does Novogene Europe have ?

Novogene Europe employs approximately 148 people worldwide.

Does Novogene Europe own any subsidiaries ?

Novogene Europe presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novogene Europe have ?

Novogene Europe's official LinkedIn profile has approximately 31,461 followers.

Does Novogene Europe have a Crunchbase profile ?

No, Novogene Europe does not have a profile on Crunchbase.

Does Novogene Europe have a LinkedIn profile ?

Yes, Novogene Europe maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novogene-europe.

How many cybersecurity incidents has Novogene Europe experienced ?

As of September 7, 2026, Rankiteo reports that Novogene Europe has not experienced any cybersecurity incidents.

How many peer or competitor companies does Novogene Europe have ?

Novogene Europe has an estimated 4,758 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novogene Europe

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novogene Europe Vendor Cyber Rating & Cyber Score

novogene.com

Add Your Compliance Badge

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise. We are now the largest sequencing center in the world. Novogene utilizes scientific excellence and unsurpassed data quality to help our clients realize their research goals. With around 2,000 employees, multiple locations around the world, and over 280 publications in top tier journal, the company has recently become the world-leader in NGS services.

Novogene Europe A.I CyberSecurity Scoring

Scoring History

Novogene Europe

Novogene Europe CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Novogene Europe Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novogene Europe

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Novogene Europe in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novogene Europe in 2026.

Incident Types Novogene Europe vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Novogene Europe in 2026.

Incident History - Novogene Europe (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novogene Europe Subsidiaries

Novogene Europe

Biotechnology Research

Website: http://en.novogene.com

Company Size: 148

NovogeneBiotechnology Research

Novogene AmericaBiotechnology

NovogeneAIT GenomicsBiotechnology Research

Loading…

Novogene Europe Similar Companies

Amgen

amgen.com

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Loading…

NEWS

Novogene Europe CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86304

SUMMARY

MojoX::Authentication versions before 0.006 for Perl allow SAML authentication bypass because parse_assertion builds Net::SAML2::Binding::POST without a trust anchor. parse_assertion in MojoX::Authentication::Model::SAML2 calls Net::SAML2::Binding::POST->new with no cacert, cert_text or anchors argument, then passes the returned XML to Net::SAML2::Protocol::Assertion->new_from_xml with the IdP signing certificate as cacert. In Net::SAML2 before 0.86 that certificate guards only encrypted assertions, so the signature on an unencrypted assertion is checked against the certificate the response itself carries. An attacker starts a SAML login, then posts a response signed with a certificate of their own. The audience, InResponseTo and timestamp checks that follow are all satisfiable by the attacker, so the response authenticates any NameID it carries.

Published

Date2026-09-06

Updated

Date2026-09-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-86232

SUMMARY

A weakness has been identified in itsourcecode Sales and Inventory System 1.0. Affected by this vulnerability is an unknown functionality of the file /pages/sup_del.php?type=supplier. Executing a manipulation of the argument ID can lead to sql injection. The attack may be performed from remote. The exploit has been made available to the public and could be used for attacks.

Published

Date2026-09-06

Updated

Date2026-09-06

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-86231

SUMMARY

A security flaw has been discovered in mwiede jsch up to 2.28.5. Affected is the function getRevokedKeys of the file src/main/java/com/jcraft/jsch/KnownHosts.java. Performing a manipulation of the argument known_hosts results in improper check for certificate revocation. The attack is possible to be carried out remotely. The attack is considered to have high complexity. The exploitability is told to be difficult. The exploit has been released to the public and may be used for attacks. Upgrading to version 2.28.6 is able to address this issue. The patch is named 194a2f76a5c0f1c3f778565be3fd66bcafc42d23. You should upgrade the affected component.

Published

Date2026-09-06

Updated

Date2026-09-06

RISK INFORMATION (Score: 3.7)

cvss2

Base Score: 2.6

Complexity: HIGH

AV:N/AC:H/Au:N/C:N/I:P/A:N

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.9

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-86228

SUMMARY

A security vulnerability has been detected in JeecgBoot up to 3.9.3. This vulnerability affects the function exportXls of the file jeecg-boot/jeecg-boot-module/jeecg-boot-module-airag/src/main/java/org/jeecg/modules/airag/llm/controller/AiragModelController.java. Such manipulation of the argument credential leads to improper access controls. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. Upgrading to version 3.9.5 is able to resolve this issue. The name of the patch is a2be896f753936956ee6863b632b8e5a0231345c. You should upgrade the affected component.

Published

Date2026-09-06

Updated

Date2026-09-06

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:N/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-86227

SUMMARY

A weakness has been identified in valkey-io valkey up to 9.0.5/9.1.1. This affects the function kvstoreGetHashtable of the file src/kvstore.c. This manipulation of the argument didx causes out-of-bounds read. It is possible to initiate the attack remotely. The attack is considered to have high complexity. It is indicated that the exploitability is difficult. The exploit has been made available to the public and could be used for attacks. Patch name: 4691888e7fab3df128f0bde5750c9fde2ae552fa. To fix this issue, it is recommended to deploy a patch. Exploitation requires cluster mode plus attacker-controlled dump.rdb at startup (data-dir write access, replication feed, or a stored crafted RDB) - an attacker-position DoS at boot, not network pre-auth. The issue report was closed stating it "is worth fixing for the sake of memory safety… but I don't think it meets our bar for a security disclosure."

Published

Date2026-09-06

Updated

Date2026-09-06

RISK INFORMATION (Score: 3.1)

cvss2

Base Score: 2.1

Complexity: HIGH

AV:N/AC:H/Au:S/C:N/I:N/A:P

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 1.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.6

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…